Special Issue "Neurodegenerative and Neurologic Disease: Genes, Mechanisms, and Therapies"
Deadline for manuscript submissions: 31 October 2023 | Viewed by 17038
Interests: neurodegeneration; genetic disease; neuronal cell polarity; tau and tauopathies; microtubules
Interests: hereditary neurodegenerative diseases; genetic pain disorders; aspects of neuronal development (dendritogenesis, cell polarity, actin cytoskeleton, primary/sensory cilia)
Treating neurodegenerative and other neurologic diseases is often challenging. Specific challenges when treating diseases of the nervous system include complex cellular interactions between neurons and glial cells, postmitotic characteristics of most neuronal cells, and cellular and supracellular compartmentalization. Furthermore, several common model systems do not fully recapitulate human disease. Hence, translation into clinics is often unsuccessful. Novel approaches to dissect disease mechanisms and the application of novel therapeutic concepts are urgently needed.
Apart from immortalized cell lines and mouse models, human-induced pluripotent cell (iPSC) lines and derived neuronal cells (e.g., neuronal precursor cells) and other vertebrate models (e.g., zebrafish) are demonstrating their usefulness in preclinical studies. In addition to pharmacological and surgical treatments, AAV-based and antisense oligonucleotide gene therapy is revolutionizing neurology. New vectors and genetic interference technologies are being constantly developed, but applications are still limited.
In this issue, we call for the submission of research articles using disease models, including human cells or animal models, as well as research on human material of affected patients. We aim to serve as a platform for studies dissecting disease mechanisms as well as the development and characterization of model systems to study human disease. We welcome studies focusing on developing and testing genetic and nongenetic therapies for human neurologic and genetic disease, in preclinical and clinical settings.
Dr. Hans Zempel
Dr. Natja Haag
Prof. Dr. Juliane Bremer
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- neurogenetic disease
- disease model
- gene therapy
- single-cell approaches